Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -3.34
- Piotroski Score 2.00
- Grade Neutral
- Symbol (FATE)
- Company Fate Therapeutics, Inc.
- Price $2.07
- Changes Percentage (-6.77%)
- Change -$0.15
- Day Low $2.01
- Day High $2.28
- Year High $8.83
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/24/2025
- Fiscal Year End N/A
- Average Stock Price Target $7.50
- High Stock Price Target $145.00
- Low Stock Price Target $4.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.92
- Trailing P/E Ratio -1.92
- Forward P/E Ratio -1.92
- P/E Growth -1.92
- Net Income $-160,928,000
Income Statement
Quarterly
Annual
Latest News of FATE
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Seahawks playoff push: Three keys that could decide Seattle's fate
The Seattle Seahawks are fighting for a playoff spot, facing critical games against the Arizona Cardinals and New York Jets. Coach Macdonald emphasizes the need for turnovers and improved run game eff...
By The New York Times | 23 hours ago -
Menendez brothers' fate in limbo: Clemency delayed as new DA takes charge
Governor Newsom respects the role of the new District Attorney-elect Hochman in reviewing the Menendez case for potential clemency decisions. Hochman plans a thorough analysis and seeks input from var...
By Newsweek | 2 days ago -
When Menendez brothers could learn their fate
The Menendez brothers, who murdered their parents in 1989, seek freedom after renewed interest in their case. New evidence and public sympathy may lead to their release, pending a clemency decision by...
By Newsweek | 2 days ago
